Newsroom | Medtronic | 2018 Press Releases

2018 Press Releases


201820172016201520142013
Search News Releases
 
DateTitle  
04/23/18Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions
New Indication Expands DCB Treatment for Patients with SFA Lesions Up to 360mm DUBLIN - April 23, 2018 - Medtronic plc (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions up to 360mm in patients with peripheral artery disease (PAD). Approval was based on clinical data from the complex lesion imaging cohorts of the IN.PACT Global Study, i... 
Download PDFPrinter Friendly Version
04/17/18Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere(TM) Embolization Spheres
Product Line Offers Unique, Resorbable Option for Patients with Hypervascular Tumors DUBLIN - April 17, 2018 - Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors. OptiSphere offers patients an alternative treatment option, a resorbable embolic, with comparable results to a permanent embolic.1 Hypervascular tumors can present as malignant or benign and can be found in v... 
Download PDFPrinter Friendly Version
04/10/18Medtronic Expands Visualase(TM) MRI-Guided Laser Ablation System to European Markets with CE Mark Approval
DUBLIN - April 10, 2018 - Medtronic plc (NYSE: MDT) announced today the CE (Conformité Européenne) Mark and European launch of the Visualase(TM) MRI-Guided Laser Ablation System. The Visualase system provides advanced MRI-guided laser ablation technology and can be used in neurosurgery procedures. With the Visualase system, laser energy is delivered to the target area using an applicator. As light is delivered through the applicator, temperatures in the target area begin to rise, destroying th... 
Download PDFPrinter Friendly Version
04/09/18Medtronic to Unveil Additional Clinical Data on HVAD® System at ISHLT 2018
Data on Implant Approach, Blood Pressure Management, Length of Stay, and Quality of Life to be Featured During Congress. DUBLIN - April 9, 2018 - Medtronic plc (NYSE: MDT) today announced a preview of notable clinical data on the HeartWare HVAD® System that will be presented at The International Society of Heart and Lung Transplantation (ISHLT) Scientific Sessions, from April 11-14, 2018, in Nice, France. The HVAD System is a mechanical heart pump (also called a left ventricular assist device,... 
Download PDFPrinter Friendly Version
04/09/18Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension
Pivotal Trial Now Underway to Study Effect of Investigational Procedure in Patients with High Blood Pressure DUBLIN - April 9, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension). Renal denervation is a minimally invasive procedure intended to regulate the activity of nerv... 
Download PDFPrinter Friendly Version
04/05/18Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
DUBLIN - April 5, 2018 - Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced Laura Mauri, M.D., M.Sc., interventional cardiologist and clinical researcher at the Brigham and Women's Hospital, and professor of medicine at Harvard Medical School, will join Medtronic as Vice President, Global Clinical Research & Analytics. Dr. Mauri will direct the company's dynamic global clinical research strategies which leverage her widely recognized clinical trial leadership and... 
Download PDFPrinter Friendly Version
03/20/18New Analyses Confirm Patients with Medtronic CRT Devices Experience Less Atrial Fibrillation, Are More Active
Positive Data on Exclusive AdaptivCRT(TM) Feature Unveiled at EHRA Scientific Sessions 2018 DUBLIN and BARCELONA, Spain - March 20, 2018 - Two real-world analyses featuring the Medtronic plc (NYSE: MDT) AdaptivCRT(TM) algorithm reinforce that its use is linked to a reduction in atrial fibrillation (AF) episodes, as well as tied to higher patient activity levels. The results, involving 408 patients with heart failure and a Medtronic cardiac resynchronization therapy (CRT) device at 26 centers i... 
Download PDFPrinter Friendly Version
03/19/18Study Shows Positive Results with Medtronic Cryoballoon for Patients with Persistent Atrial Fibrillation
DUBLIN and BARCELONA, Spain - MARCH 19, 2018 - Medtronic plc (NYSE: MDT) today announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance(TM) Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF). The Arctic Front Advance Cyroablation System is not approved for treating persistent AF in the United States. The study results, presented today at the European Heart Rhythm Association (EHRA) Scientific ... 
Download PDFPrinter Friendly Version
03/13/18Medtronic EVP & President Hooman Hakami to Speak at Oppenheimer Healthcare Conference
DUBLIN - March 13, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City. Hooman Hakami, executive vice president and group president of Medtronic's Diabetes Group, will answer questions about the company beginning at 8:35 a.m. EDT (7:35 a.m. CDT). A live audio webcast of the presentation will be available on March 20, 2018, by clicking on t... 
Download PDFPrinter Friendly Version
03/12/18Medtronic Receives FDA Approval for Guardian Connect Continuous Glucose Monitoring (CGM) System for People Living with Diabetes
'Smart' CGM System Provides Predictive Alerts for Dangerous Sensor Glucose Levels; Exclusive Access to Sugar.IQ Assistant with Watson Offers More Proactive Diabetes Management DUBLIN - March 12, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today announced it received U.S. Food and Drug Administration (FDA) approval for its Guardian(TM) Connect continuous glucose monitoring (CGM) system, for people with diabetes ages 14 to 75 years. The Guard... 
Download PDFPrinter Friendly Version
03/12/18Applications Now Open for the 2018 Medtronic Global Champions Team
Medtronic Seeks Up to 20 Runners Who Benefit from Medical Technology Selected Runners Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October 2018 Applications Accepted at www.medtronic.com/globalchampions DUBLIN - March 12, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that applications are now being accepted for the 2018 Medtronic Global Champions team. This annual program brings together runners from... 
Download PDFPrinter Friendly Version
03/10/18Clinical Trials Show Strong Long-Term Performance with the Medtronic CoreValve TAVR System
Presented at ACC.18, Five-Year Follow-up from the CoreValve Extreme Risk and NOTION Studies Show Sustained Valve Function and Durability Over Time DUBLIN and ORLANDO - March 10, 2018 - Medtronic plc (NYSE: MDT) today unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (Nordic Aortic Valve Intervention Trial), both of which examined patients with the CoreValve(TM) transcatheter aortic valve replacement (TAVR) system at five years post-implant. Pre... 
Download PDFPrinter Friendly Version
03/09/18Medtronic EVP & CFO Karen Parkhill to Speak at Barclays Healthcare Conference
DUBLIN - March 9, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will answer questions about the company on Wednesday, March 14, 2018, in Miami, Florida. Karen Parkhill, executive vice president and chief financial officer of Medtronic, will answer questions about the company beginning at 10:15 a.m. EDT (9:15 a.m. CDT). A live audio webcast of the presentation will be available on March 14, 2018, by clicking on the Investors Events link at http://i... 
Download PDFPrinter Friendly Version
03/09/18Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2018
DUBLIN - March 9, 2018 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2018 fourth quarter cash dividend of $0.46 per ordinary share, representing a 7 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2017.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 40 consecutive years. The dividend is pa... 
 Printer Friendly Version
03/08/18Medtronic EVP & CVG President Mike Coyle to Speak at Cowen Healthcare Conference
DUBLIN - March 8, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 38th Annual Cowen and Company Healthcare Conference on Tuesday, March 13, 2018, in Boston, Massachusetts. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group (CVG), will answer questions about the company beginning at 9:20 a.m. EDT (8:20 a.m. CDT). A live audio webcast of the presentation will be available on March 13, 2... 
Download PDFPrinter Friendly Version
02/28/18Medtronic and Lehigh Valley Health Network Sign Strategic Partnership Agreement Focused on Delivering Value-Based Healthcare Programs
The Programs Are Expected to Benefit up to 500,000 Patients in Northeast Pennsylvania and Reduce Cost of Care by $100 Million LEHIGH VALLEY, Pa. and DUBLIN - February 28, 2018 - Today, Medtronic plc (NYSE: MDT), the global leader in medical technology, and Lehigh Valley Health Network (LVHN), an eight-hospital network serving seven counties in Northeastern Pennsylvania, have announced a five-year strategic partnership aimed at developing innovative, sustainable, and integrated value-based solut... 
Download PDFPrinter Friendly Version
02/26/18Medtronic Launches First 2.0 mm Drug-Eluting Stent in United States Designed to Treat Patients with Small Vessels
FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients DUBLIN - February 26, 2018 - Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) 2.0 mm Drug-Eluting Stent (DES) - the smallest sized DES on the market. The new stent is intended to help interventional cardiologists treat pati... 
Download PDFPrinter Friendly Version
02/26/18Medtronic Receives FDA Approval for New Arm Indication for Guardian(TM) Sensor 3 - Further Enhancing the MiniMed(TM) 670G Hybrid Closed Loop Experience
DUBLIN- February 26, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian(TM) Sensor 3. This expanded indication will enable patients to wear the sensor on the upper arm - delivering more flexibility and enhanced performance for users, as well as improved accuracy, with a MARD of 8.7 percent following typical calibration methods used with the MiniMed(TM) 670G s... 
Download PDFPrinter Friendly Version
02/21/18NICE Issues Medtech Innovation Briefing Recognizing Medtronic Reveal LINQ in the Detection of Atrial Fibrillation After Stroke of Unknown Cause
DUBLIN - February 21, 2018 - Today, the United Kingdom's National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing on the use of the Medtronic Reveal LINQ(TM) insertable cardiac monitor (ICM) with the Medtronic CareLink® Network, highlighting the device's benefits in detecting suspected atrial fibrillation (AF) after a stroke of unknown cause (cryptogenic stroke), which includes cryptogenic transient ischaemic attack (TIA) and embolic stroke of undetermined so... 
Download PDFPrinter Friendly Version
02/21/18Medtronic Introduces MiniMed(TM) Mio(TM) Advance Infusion Set for People with Diabetes
New Infusion Set Offers Simpler, Faster, and More Convenient1 Insulin Pump Experience DUBLIN - February 21, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, today introduced the MiniMed(TM) Mio(TM) Advance infusion set. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives patients a simpler, faster and more convenient set change with fewer steps1,2. The new infusion set will first be ava... 
Download PDFPrinter Friendly Version
02/20/18Medtronic Reports Third Quarter Financial Results
Revenue of $7.4 Billion Increased 1% as Reported; 7% at Comparable, Constant Currency  GAAP Diluted LPS of $1.03; Non-GAAP Diluted EPS of $1.17 Company Reiterates Full Year Revenue and EPS Guidance  DUBLIN - February 20, 2108 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018. The company reported third quarter worldwide revenue of $7.369 billion, an increase of 1 percent as reported, or 7 percent on a com... 
 Printer Friendly Version
02/16/18Medtronic Chairman and CEO Omar Ishrak to Speak at CEO Investor Forum 3.0
DUBLIN - February 16, 2018 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the CECP CEO Investor Forum 3.0 in New York on Monday, February 26, 2018, at 4:00 p.m. EST. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a formal presentation on the company beginning at 4:00 p.m. EST (3:00 p.m. CST).  A live audio webcast of the presentation will be available on February 26, 2018, by clicking on the Investor Even... 
 Printer Friendly Version
02/15/18New Pediatric At-Home Study of MiniMed(TM) 670G System Demonstrates Positive Results in Children Ages 7 to 13
DUBLIN and VIENNA - February 15, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria. Study results mirror data from the pivotal trial of the system in adults and adolescents (14 and above), showing patients spent more Time in R... 
Download PDFPrinter Friendly Version
02/13/18Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2018
DUBLIN - February 13, 2018 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the third quarter of fiscal year 2018 on Tuesday, February 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2018, which ended on Friday, January 26, 2018. Medtronic will host a... 
Download PDFPrinter Friendly Version
02/13/18Medtronic Announces Upcoming Data Presentations at the Advanced Technologies and Treatments for Diabetes 11th International Conference
Medtronic Will Host an Exclusive Symposium on Thursday, February 15 VIENNA - February 13, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria, from February 14-17. A significant portion of the scientific data being presented focuses on the company's insulin pump systems, including new data on ... 
Download PDFPrinter Friendly Version
01/30/18Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
DUBLIN and SHANGHAI - January 30, 2018 - Medtronic plc (NYSE:MDT) today announced that Alex Gu, previously Vice President, Regional Growth Initiatives, Greater China, and leader of Medtronic's Minimally Invasive Therapies Group (MITG) in Greater China, has been named Senior Vice President and President of Medtronic's Greater China Region. Medtronic's Greater China Region includes mainland China, Hong Kong SAR, and the Taiwan region. Gu will serve on the company's Executive Committee and succeeds... 
Download PDFPrinter Friendly Version
01/30/18Medtronic and Philips Partner to Innovate in Lung Cancer Management
Healthcare Leaders Join to Streamline and Optimize the Management of Lung Nodules DUBLIN and AMSTERDAM - January 30, 2018 - In a collective effort to improve the management of patients with lung nodules, Medtronic plc (NYSE: MDT) and Royal Philips (NYSE: PHG; AEX: PHIA) have entered into a business relationship to develop and commercialize the LungGPS(TM) Patient Management Platform. The comprehensive patient and data management platform is designed to streamline the management of lung nodule ... 
Download PDFPrinter Friendly Version
01/30/18IN.PACT Admiral Demonstrates Consistent and Durable Outcomes in New Two-Year Japan Data and IN.PACT Global Critical Limb Ischemia Cohort Analysis
Data Presented at LINC 2018 Highlight IN.PACT Admiral as Safe and Effective Treatment Option in PAD DUBLIN and LEIPZIG - January 30, 2018 - Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease (PAD). The new data presented at the Leipzig Interventional Course (LINC) in Leipzig, Germany, included t... 
Download PDFPrinter Friendly Version
01/26/18Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease
Study to Enroll Subjects at up to 35 Sites Across the U.S. and Europe DUBLIN - January 26, 2018 - Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent in subjects with iliofemoral venous outflow obstruction. The first procedure was performed in December of 2017, by Dr. Erin Murphy, director of the venous and ... 
Download PDFPrinter Friendly Version
01/24/18Medtronic Launches ENCHANT Study to Evaluate ChEVAR Parallel Graft Technique with the Endurant(TM) II/IIs Stent Graft System
Clinical Study to Investigate the Performance of the ChEVAR Technique in AAA Patients with Short Aortic Necks DUBLIN - January 24, 2018 - Medtronic plc (NYSE: MDT) today announced the launch of the ENCHANT (ENdurant CHEVAR New Indication Trial) study. The post-market, non-interventional, multi-center, non-randomized, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant... 
Download PDFPrinter Friendly Version
01/16/18Medtronic Receives FDA Clearance for Riptide(TM) Aspiration System
New System Expands Neurovascular Product Portfolio for the Treatment of Acute Ischemic Stroke DUBLIN - January 16, 2018 - Medtronic plc (NYSE:MDT) today announced that the company's Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide(TM) Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. The Riptide Aspiration System is designed to retrieve thrombus (or blood clot) through the Arc(TM) Catheter and r... 
Download PDFPrinter Friendly Version
01/11/18New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity
Therapy Delivered via the Medtronic SynchroMed(TM) II Infusion System DUBLIN - January 11, 2018 - Medtronic plc (NYSE:MDT) today announced the publication of results from the 'Spasticity In Stroke-Randomised Study' (SISTERS) trial in the Journal of Neurology, Neurosurgery & Psychiatry (JNNP). These results demonstrate the superiority of Medtronic ITB TherapySM with Lioresal®Intrathecal (baclofen injection) delivered via the SynchroMed(TM) II Infusion System compared to conventional medical ... 
 Printer Friendly Version
01/10/18FDA Approves Innovative Clinician Programmer for the Medtronic SynchroMed II Intrathecal Drug Delivery System for Chronic Pain and Severe Spasticity
SynchroMed(TM) II for Chronic Pain Is an Alternative to Systemic Opioids for Many Patients DUBLIN - January 10, 2018 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of a new clinician programmer for use with the SynchroMed(TM)II Intrathecal Drug Delivery system, an implantable pump that provides targeted drug delivery for chronic pain and severe spasticity. The SynchroMed II pump delivers medication directly to the fluid around the spinal cord, which... 
Download PDFPrinter Friendly Version
01/09/18Medtronic Enrolls First Patient In Pain Study to Assess Optimized Spinal Cord Stimulation Programming
As More Physicians Seek Non-Opioid Treatment Options, the Vectors Study Will Further Advance Understanding of New Approaches to Optimal Spinal Cord Stimulation Treatment DUBLIN - January 9, 2018 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable pain who are undergoing spinal cord stimulation (SCS) treatment managed with the EvolveSM workflow*, which standardizes guidance that ... 
Download PDFPrinter Friendly Version
X